Results 131 to 140 of about 104,287 (300)

Duration‐Dependent Efficacy and Clinical Safety of Repeated Low‐Level Red‐Light Therapy for Paediatric Myopia: A Systematic Review and Meta‐Analysis

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Repeated low‐level red‐light (RLRL) therapy is a novel, non‐invasive intervention for controlling paediatric myopia progression. Despite increasing clinical use, questions remain regarding the magnitude, durability, and safety of treatment effects.
Lee‐Yuan Lin   +8 more
wiley   +1 more source

Algorithms of Patient Selection for Allergen Immunotherapy

open access: yes
Allergy, EarlyView.
U. Petra Zieglmayer   +5 more
wiley   +1 more source

Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis [PDF]

open access: yes, 2017
Dahdah, Lamia   +2 more
core   +1 more source

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi   +13 more
wiley   +1 more source

Avian chlamydiosis [PDF]

open access: yes, 2018
B
Laroucau, Karine   +2 more
core   +1 more source

Incorporation of two terminology projects into a system for information retrieval using NLP for term expansion [PDF]

open access: yes, 2007
In this paper, we will discuss two medical terminology projects at the University College of Ghent, Faculty of translation studies, and the benefits of combining them to provide Dutch professionals and laymen with better access to information in ...
Van Wiele, Kurt, Vanopstal, Klaar
core   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo   +11 more
wiley   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault   +51 more
wiley   +1 more source

Automated Detection of Systematic Off-label Drug Use in Free Text of Electronic Medical Records. [PDF]

open access: yes, 2013
Off-label use of a drug occurs when it is used in a manner that deviates from its FDA label. Studies estimate that 21% of prescriptions are off-label, with only 27% of those uses supported by evidence of safety and efficacy.
Jung, Kenneth   +2 more
core   +2 more sources

Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The results of this French Early Access Program were consistent with those reported in dupilumab randomized clinical trials in children aged 6 months–5 years with moderate‐to‐severe AD. This research offers insights into the practical use of dupilumab in routine clinical practice.
Audrey Lasek   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy